Kenneth Anderson, MD
Pulmonary Disease · Louisville, KYNPI 1205800034
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,093 of the $16,376 with a category attached, or 86.1%. Bristol Myers Squibb accounts for 91.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $14,479 and has fallen 96.5% since, to $507 in 2025.
Across 65 payments — averaging $251.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$15K
- Harmony Biosciences LLC$435
- Axsome Therapeutics, Inc.$299
- Jazz Pharmaceuticals Inc.$287
- Philips North America LLC$141
- Lilly USA, LLC$74
- plus $164 from 5 others
Across 1 payment — averaging $114.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$114
What the payments were for
- Consulting fees$14,09386%
- Travel & lodging$8845%
- Food & beverage$1,3008%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 5 | $14,976 |
| Harmony Biosciences LLC | 17 | $435 |
| Axsome Therapeutics, Inc. | 13 | $299 |
| Jazz Pharmaceuticals Inc. | 14 | $287 |
| Philips North America LLC | 3 | $141 |
| Lilly USA, LLC | 5 | $74 |
| Inspire Medical Systems, Inc. | 3 | $63 |
| Bioventus LLC | 2 | $41 |
| Itamar Medical Inc | 1 | $27 |
| Fisher & Paykel Healthcare Inc | 1 | $18 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mask$112
How this compares
$16,376 in reported general payments places this provider in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArexvyRsvpref3 Antigen/As01e/Pf | 89 | $25,782 |
| NeuproRotigotine | 11 | $9,105 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 41 | $8,611 |
| Modafinil | 37 | $7,095 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 18 | $1,169 |
| Zolpidem Tartrate | 60 | $416 |
| Amitriptyline Hcl | 36 | $384 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $226 |
| Eszopiclone | 23 | $221 |
| Clonazepam | 21 | $169 |
| Ropinirole Hcl | 13 | $160 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Louisville
- John McConnellLouisville$864K
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Maroun GhosseinLouisville$34K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Mohamed SaadLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.